TCG Advisory Services LLC Has $583,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)

TCG Advisory Services LLC lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 64.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,635 shares of the company’s stock after purchasing an additional 2,218 shares during the period. TCG Advisory Services LLC’s holdings in Novo Nordisk A/S were worth $583,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of NVO. Jennison Associates LLC boosted its stake in shares of Novo Nordisk A/S by 100.3% in the 3rd quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock valued at $2,129,761,000 after purchasing an additional 11,727,507 shares during the last quarter. FMR LLC raised its position in shares of Novo Nordisk A/S by 122.7% in the 3rd quarter. FMR LLC now owns 12,077,501 shares of the company’s stock worth $1,098,328,000 after acquiring an additional 6,654,614 shares in the last quarter. Morgan Stanley lifted its stake in shares of Novo Nordisk A/S by 96.5% in the 3rd quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock valued at $838,021,000 after purchasing an additional 4,526,199 shares during the period. Loomis Sayles & Co. L P boosted its position in shares of Novo Nordisk A/S by 91.7% during the 3rd quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock valued at $827,354,000 after purchasing an additional 4,350,862 shares in the last quarter. Finally, Polen Capital Management LLC acquired a new stake in Novo Nordisk A/S during the third quarter worth approximately $718,995,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 0.8 %

Shares of NYSE:NVO traded down $0.97 during midday trading on Friday, hitting $123.05. 5,932,926 shares of the company’s stock were exchanged, compared to its average volume of 3,905,318. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $138.28. The company has a market cap of $552.19 billion, a PE ratio of 42.43, a price-to-earnings-growth ratio of 2.06 and a beta of 0.43. The stock has a 50 day moving average price of $127.20 and a 200-day moving average price of $113.10.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 92.21% and a net margin of 36.56%. The firm had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on NVO shares. UBS Group started coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating on the stock. BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Finally, Morgan Stanley initiated coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.